Skip to content

ETTE

Evaluation of access times endometrial carcinoma treatment - ETTE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON58456
Enrollment
750
Registered
2026-02-19
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial carcinoma Endometrial cancer

Interventions

Not applicable.

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patient has a histologically confirmed endometrial carcinoma and was treated in one of the hospitals in southwest Netherlands (IKNL region).

Exclusion criteria

Exclusion criteria: Patients with a diagnosis other than endometrial carcinoma and patients who were treated outside the southwest Netherlands region.

Design outcomes

Primary

MeasureTime frame
Duration from diagnosis to start of treatment (surgery, radiotherapy, chemotherapy) and duration between consecutive treatments.

Secondary

MeasureTime frame
“Are there differences in the duration of treatments between the hospitals?”“When were patients discussed in the MDT, and did this lead to delays?”“How long did it take after referral to a colleague before treatment was initiated?”

Countries

Netherlands

Contacts

Public ContactH.J. Beekhuizen

Erasmus MC, Universitair Medisch Centrum Rotterdam

gyn.oncoresearch@erasmusmc.nl010-704 0704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Mar 20, 2026